2022 NIAID Omnibus Broad Agency Announcement
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA-2022-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Oregon Health & Science University
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93023C00002 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University a cost-reimbursement contract valued at $15,010,424 to develop a small molecule inhibitor drug candidate against Chikungunya virus under contract number 75N93023C00002. This type of contract was selected as costs for drug development cannot be adequately defined at time of award. Oregon Health & Science University will carry out development of a drug to treat the debilitating and life-threatening disease caused by the alphavirus Chikungunya virus.
Notice text
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. This contract is to carry out development for a drug candidate small molecule inhibitor against Chikungunya virus, an alphavirus that causes debilitating and sometimes life-threatening disease in humans.
Awarded contract 75N93023C00002 to Oregon Health & Science University for 15010424.00 on 2022-11-01.
Notice history
| Notice | Type | Posted |
|---|---|---|
| 2022 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| This notice | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Solicitation | |
| 2022 NIAID Omnibus Broad Agency Announcement | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity